SESSION I
Histopathology, biology and... other
Histology
E.S. JaffeEpigenetic evolution in lymphoma
A.M. MelnickGenetic landscape of DLBCL
R. Dalla FaveraMechanism-based therapy of DLBCL
M. RoschewskiSESSION II
Precision medicine in DLBCL
Molecular predictors of response
B. ChapuySESSION III
Specific therapeutical approaches in DLBCL
Role of radiotherapy
U. RicardiCNS prophylaxis
K. CwynarskiSESSION IV
Update on frontline treatments and beyond
How to treat early stage DLBCL
A. Lopez-GuillermoAdvanced stage: moving beyond R-CHOP
G.S. NowakowskiFocus on high-risk patients
J.C. ChavezHow to treat elderly patients
P.J. LugtenburgSESSION V
Bispecifics
Epcoritamab
P.J. LugtenburgGlofitamab
M. HutchingsOdronextamab
W. KimMosunetuzumab
E.L. BuddeSESSION VI
CAR T-Cell in DLBCL and MCL
Third Line DLBCL: Juliet study and RWD
S.J. SchusterThird Line DLBCL: Transcend study and RWD
J.S. AbramsonSecond Line DLBCL: TRANSFORM study
J.S. AbramsonThird line MCL: ZUMA-2 and RWD
M. WangSESSION VII
New drugs in DLBCL (I)
Polatuzumab vedotin
L. SehnTafasitamab + Lenalidomide
J.A. DuellLoncastuximab tesirine
C. Carlo-StellaZilovertamab vedotin
M. WangSESSION VIII
New drugs in DLBCL (II)
CC-99282
J.M. MichotIberdomide
J.L. MunozCDK9 inhibitor
C.A. PortellSESSION IX
Other aggressive entities and situations